AN HTLV-I VACCINE - WHY, HOW, FOR WHOM
AN HTLV-I VACCINE - WHY, HOW, FOR WHOM
复制标题
DOI：
10.1089/aid.1993.9.381
复制
发表时间：
1993-05-01
影响因子：
1.5
通讯作者：
BOMFORD, R
中科院分区：
文献类型：
--
作者：
DETHE, G;BOMFORD, R
人类T细胞白血病/淋巴瘤病毒I和II （HTLV-I/II）的地方性感染现在被认为是世界性的，并且正在成为美国和欧洲静脉注射吸毒者（ivda）的流行病。全世界感染HTLV-I的人数估计在1000万至2000万之间（表1）。HTLV-I可导致快速进展的成人T细胞白血病/淋巴瘤（ATLL）和一种无法治愈的进行性神经脊髓病，称为热带痉挛性麻痹/HTLV-I相关脊髓病（TSP/HAM），以及一些研究较少的综合征。有证据表明，HTLV-I或-II合并感染加速了艾滋病的进展。发生ATLL或TSP/HAM的累积终生风险约为5%，就诱发严重疾病而言，htlv - 1属于已研制和使用有效疫苗的同一类病毒。此外，有一些因素支持HTLV-I疫苗的可行性，因为该病毒表现出相对较低的抗原变异性，在人类中发生自然免疫，并且在动物模型中使用包膜（Env）抗原进行实验性疫苗接种是成功的。针对htlv - 1的疫苗将在肿瘤学、神经学和艾滋病领域具有重要的公共卫生价值，并将成为针对HIV疫苗的探路者。
Endemic infection with the human T cell leukemia/lymphoma viruses I and II (HTLV-I/II) is now recognized to be worldwide, and is becoming epidemic among intravenous drug abusers (IVDAs) in the United States and Europe. The number of people around the world infected with HTLV-I can be estimated as between 10 and 20 million (Table 1). HTLV-I causes a rapidly progressing adult T cell leukemia/lymphoma (ATLL), and an incurable progressive neuromyelopathy named tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM), as well as a number of less well-studied syndromes. There is evidence that coinfection with HTLV-I or -II accelerates progression to AIDS. The cumulative lifetime risk of developing ATLL or TSP/HAM is around 5%, which, in terms of the induction of serious diseases, places HTLV-I in the same category of viruses for which efficient vaccines are made and used. Furthermore, there are factors favoring the feasibility of a vaccine against HTLV-I, in that the virus displays relatively low antigenic variability, natural immunity occurs in humans, and experimental vaccination with the envelope (Env) antigen is successful in animal models. A vaccine against HTLV-I would be of significant public health value in the fields of oncology, neurology, and AIDS, and it would serve as a pathfinder for a vaccine against HIV.